Data on 1,530 patients with rheumatoid arthritis (RA) in a real-life cohort from the CERERRA collaboration show that repeated cycles of rituximab provides clinical improvements. A significant (P < 0.0001) reduction in mean 28-joint disease activity score (DAS28) occurred between each round of retreatment, suggesting an improvement in disease. In a second analysis of 800 patients from the cohort, a fixed-interval treatment strategy was more effective than on-flare treatment, with the former yielding a lower average DAS28 (3.8 versus 4.6).
References
Chatzidionysiou, K. et al. Rituximab retreatment in rheumatoid arthritis in a real-life cohort: data from the CERERRA collaboration. J. Rheumatol. http://dx.doi.org/10.3899/jrheum.160460 (2017)
Rights and permissions
About this article
Cite this article
Collison, J. Retreatment with rituximab is beneficial in RA. Nat Rev Rheumatol 13, 130 (2017). https://doi.org/10.1038/nrrheum.2017.12
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.12